American Society of Hypertension & American Urological Association

Some of the topics covered at the ASH sessions were fixed-dose combinations (Lotrel, Lotensin, Benicar HCT, and Azor) as well as an endothelin receptor agonist (darusentan). Therapies presented at the AUA meeting included dutasteride (Avodart) for reducing the risk of prostate cancer; a topical gel of oxybutynin chloride (Gelnique) for treating patients with overactive bladder; and silodosin (Rapaflo) for decreasing symptoms of benign prostatic hyperplasia.